Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 397(1): 75-84, 2000 May 26.
Article in English | MEDLINE | ID: mdl-10844101

ABSTRACT

The effect of gamma-hydroxybutyrate on the histological and behavioral consequences of transient brain ischemia was studied in the four vessel occlusion rat model. In saline-treated animals, 30 min ischemia caused a massive loss of neurons in the hippocampal CA1 subfield (normal neurons: 14%, 5%, 23% and 30% on the 3rd, 10th, 15th and 65th day after ischemia, respectively). gamma-Hydroxybutyrate - 300 mg/kg intraperitoneally (i.p.) 30 min before or 10 min after arteries occlusion, followed by 100 mg/kg i.p. twice daily for the following 10 days - afforded a highly significant protection (normal neurons on the 3rd, 10th, 15th and 65th day after ischemia: 88% and 91%, 80% and 80%, 91% and 90%, 72% and 71% in rats receiving the first dose before or after arteries occlusion, respectively). The ischemia-induced sensory-motor impairment was significantly attenuated in rats receiving the first dose of gamma-hydroxybutyrate before arteries occlusion. Finally, the ischemia-induced impairment in spatial learning and memory, evaluated starting 27 days after the ischemic episode, was significantly attenuated by gamma-hydroxybutyrate, either injected first at 30 min before or 10 min after arteries occlusion. Lower doses of gamma-hydroxybutyrate had no significant effect. In conclusion, these results indicate that gamma-hydroxybutyrate provides significant protection against both histological and behavioral consequences of transient global cerebral ischemia in rats.


Subject(s)
Brain Ischemia/physiopathology , Hippocampus/drug effects , Neuroprotective Agents/pharmacology , Sodium Oxybate/pharmacology , Animals , Hippocampus/pathology , Learning/drug effects , Male , Memory/drug effects , Neurons/drug effects , Neurons/pathology , Psychomotor Performance/drug effects , Rats , Rats, Wistar , Somatosensory Cortex/drug effects , Somatosensory Cortex/physiopathology , Spatial Behavior/drug effects
2.
Alcohol Alcohol ; 33(2): 126-30, 1998.
Article in English | MEDLINE | ID: mdl-9566474

ABSTRACT

The present study assessed the efficacy of the cannabinoid CB1 receptor antagonist, SR-141716, in reducing voluntary ethanol intake in selectively bred Sardinian alcohol-preferring (sP) rats. Ethanol (10%, v/v) and food were available in daily 4 h scheduled access periods; water was present 24 h/day. The acute administration of a 2.5 and a 5 mg/kg dose of SR-141716 selectively reduced ethanol intake, whereas a 10 mg/kg dose of SR-141716 reduced to a similar extent both ethanol and food intake. These results suggest that the cannabinoid CB1 receptor is involved in the mediation of the ethanol-reinforcing effects in sP rats.


Subject(s)
Alcohol Drinking/drug therapy , Cannabinoids/antagonists & inhibitors , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Alcohol Drinking/genetics , Alcohol Drinking/psychology , Animals , Central Nervous System Depressants/blood , Drinking/drug effects , Eating/drug effects , Ethanol/blood , Male , Rats , Rats, Inbred Strains , Rats, Wistar , Receptors, Cannabinoid , Receptors, Drug/antagonists & inhibitors , Rimonabant
SELECTION OF CITATIONS
SEARCH DETAIL
...